Follow-On Biologics Studies Depend On “Switchability”, MDS Pharma Says

"Switchable" follow-on biologics should only require Phase III safety studies after pharmacokinetic/ pharmacodynamic bioequivalency has been shown in Phase I, MDS Pharma Services VP-PK/PD Murray Ducharme suggested